此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects

2017年12月24日 更新者:Shenyang Sunshine Pharmaceutical Co., LTD.

A Randomized, Double Blind, Placebo Controlled Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation to Explore the Tolerance, Safety and Pharmacokinetic Characteristics in Healthy Subjects

This study is a randomized, double-blind and placebo-controlled trial with healthy subjects. There are 6 Groups as follows: 5mg, 15mg, 30mg, 50mg, 75mg, 100mg, and each group includes12 people. A single subcutaneous injection will be administrated starting from the low dose group (in accordance with 5mg, 15mg, 30mg, 50mg, 75mg, 100mg administered subcutaneously). Pharmacokinetics and pharmacodynamics data will be collected; drug metabolism and pharmacokinetics characteristics will be analyzed. Drug safety and tolerance for subjects will be evaluated.

研究概览

详细说明

This study is a randomized, double-blind and placebo-controlled trial with healthy subjects. There are 6 Groups as follows: 5mg, 15mg, 30mg, 50mg, 75mg, 100mg, and each group includes12 people. A single subcutaneous injection will be administrated starting from the low dose group (in accordance with 5mg, 15mg, 30mg, 50mg, 75mg, 100mg administered subcutaneously). Pharmacokinetics and pharmacodynamics data will be collected; drug metabolism and pharmacokinetics characteristics will be analyzed. Drug safety and tolerance for subjects will be evaluated.

The study observed blood concentrations of the experimental drug at different time points after and before administration, TNFα before and after treatment at different time points will be observed as well.

C-T curve will be drawn with blood drug concentration (c) and time (T) in the trial. At the same time, the investigators will draw the average plasma concentration curve. Compartmental and non compartmental model will be used to analyze the pharmacokinetic parameters of subjects. It will be judged with linear or nonlinear elimination by the correlation analysis of AUC, Cmax of different doses. In the meantime, adverse events, vital signs, physical examination, laboratory examination and ECG will be evaluated.

研究类型

介入性

注册 (实际的)

72

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Beijing
      • Beijing、Beijing、中国、100044
        • Peking University People's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. healthy adult volunteers who are voluntary to participate in clinical trials, and signed the informed consent
  2. aged 18-45 years, the same batch of subjects age difference is less than or equal to 10 years of age
  3. subjects with qualified physical examination within 7 days before the trial, body mass index (BMI) from19 to 24 ,and the same batch of subjects are with the similar weight
  4. the basic indicators of heart, liver, kidney and blood examination are in the normal range.

Exclusion Criteria:

  1. subjects are during the acute or chronic infection period, or have a previous history of active tuberculosis
  2. subjects are with the history of diseases of the central nervous system, cardiovascular system, kidney, liver (specific indexes of liver function), digestive system ,respiratory system or metabolic system or suffered from other significant disease
  3. subjects as allergic constitution after inquiry, suspected or confirmed or have a history of drug, food allergy , or subjects with a clear history of allergies and / or allergic to the humanized TNF alpha monoclonal antibody or the ingredient of humanized TNF alpha monoclonal antibody , or serum immunoglobulin E (IgE) examination was abnormal
  4. subjects are included in other clinical trials of other drugs 3 months before being enrolled in this clinical trial, or candidates used drugs known to have damage to the main organs within 3 months before this trial;
  5. candidates with blood donation history 3 months before being enrolled
  6. Prescription and non prescription drugs were administrated Within 2 weeks before inclusion
  7. ALT or AST > 1.5N (the upper limit of normal), Cr>N (the upper limit of normal);
  8. leukocyte absolute value less than 3.50 × 109/L or > 9.50× 109/L, neutrophil absolute value less than 1.8× 109/L, platelet counts less than 100 × 109/L, hemoglobin is less than 100g/L
  9. hepatitis B surface antigen (HbsAg), hepatitis C antibody (HCV-Ab), acquired immunodeficiency syndrome (Anti-HIV) antibody and anti Treponema pallidum antibody (TP-Ab) are positive subjects
  10. candidates with positive tuberculin skin test with 5 unit dose tuberculin , the size of 48-72 hour scleroma greater than 5 mm
  11. subjects with positive anti nuclear antibodies (ANA, ds-DNA, ENA)
  12. subjects with positive resistantance antibody
  13. subjects had a history of mental illness
  14. subjects who are pregnant, lactating women or a planning pregnant within 3 months
  15. subjects with the history of orthostatic hypotension
  16. with drug or drug abuse history after inquiry
  17. daily smoking more than 5 cigarettes or the same amount of tobacco after inquiry
  18. subjects drink more than 28 units of alcohol after inquiry, or alcohol breath test are positive within 24 hours before the acceptance of the tested drugs
  19. There is a family history of cancer
  20. Significantly abnormal values in clinical appeared during the screening
  21. subjects cannot understand, exchangeand cooperate enough, and cannot guarantee the researchers according to the scheme
  22. researchers don't think it is right to participate in the research with other reasons.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo group
The arm is as a control group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
Subcutaneous injection of different doses for healthy people
实验性的:experimental group
The arm is as an experimental group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.

Subcutaneous injection of different doses for healthy people

Subcutaneous injection of different doses in healthy people

其他名称:
  • TNFα monoclonal antibody

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
AUC
大体时间:28 days
AUC
28 days
Cmax
大体时间:28 days
Cmax
28 days
Cmin
大体时间:28 days
Cmin
28 days
Tmax
大体时间:28 days
Tmax
28 days

次要结果测量

结果测量
措施说明
大体时间
Serum creatinine and AST and ALT
大体时间:28 days
Serum creatinine and AST and ALT
28 days
or any other adverse events
大体时间:28 days
or any other adverse events
28 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年5月1日

初级完成 (实际的)

2015年11月1日

研究完成 (实际的)

2015年11月1日

研究注册日期

首次提交

2015年1月18日

首先提交符合 QC 标准的

2015年5月29日

首次发布 (估计)

2015年6月2日

研究记录更新

最后更新发布 (实际的)

2017年12月27日

上次提交的符合 QC 标准的更新

2017年12月24日

最后验证

2017年12月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅